Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | See Remarks | March 11, 2026 | March 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atea Pharmaceuticals, Inc.
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 823,576 |
Reported balance
After 2026-03-11 transaction · row 1
1 source rowRow 1 · 2026-03-11 · Exercise / conversion · Acquired 60,000 · Balance 823,576 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2026-12-08 | Direct | 0 |
Reported balance
After 2026-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-11 · Exercise / conversion · Acquired 60,000 · Balance 0 F1: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2026 Filed Mar 13, 2026 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001193125-26-106547 · ownership.xml · derivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 60,000 | $1.24 | $74,400.00 |
DisclosureSEC source: 0001193125-26-106547 · ownership.xml · nonDerivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 5 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-01-30 F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 4 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 44,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 3 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. F3 · derivative.expiration_date: The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 16,104 | $4.24 | $68,280.96 |
DisclosureSEC source: 0001193125-26-036269 · ownership.xml · nonDerivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,576 Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 54,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036269 · ownership.xml · nonDerivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 7,507 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 6 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-01-30 F6 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 5 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. F5 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 44,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 4 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,366 Underlying: Common Stock · 44,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F4 · derivative.expiration_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 16,102 | $3.06 | $49,272.12 |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 3 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717,307 Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,409 F3 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs"). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 44,367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 722,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 8,334 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:31 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 15,843 | $3.84 | $60,914.75 |
DisclosureSEC source: 0000950170-24-010973 · ownership.xml · nonDerivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 670,208 F3 · shares: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:31 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-010973 · ownership.xml · derivative · entry 4 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-30 F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:31 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 44,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010973 · ownership.xml · derivative · entry 3 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,733 Underlying: Common Stock · 44,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F4 · derivative.expiration_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:31 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 44,367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-010973 · ownership.xml · nonDerivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 8,680 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 186,300 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-23-003607 · doc4.xml · derivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,300 Underlying: Common Stock · 186,300 shares Expires 2033-01-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 133,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003607 · doc4.xml · derivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,100 Underlying: Common Stock · 133,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. F2 · derivative.expiration_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:15 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 181,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0000899243-22-004184 · doc4.xml · derivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,000 Underlying: Common Stock · 181,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 16:52 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 148,850 | $0.00 Strike: $73.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003869 · doc4.xml · derivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,850 Underlying: Common Stock · 148,850 shares Expires 2031-01-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 20:08 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries B Convertible Preferred Stock · Derivative | 33,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030330 · doc4.xml · derivative · entry 3 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 20:08 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries A Convertible Preferred Stock · Derivative | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030330 · doc4.xml · derivative · entry 2 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 20:08 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionCommon Stock | 133,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030330 · doc4.xml · nonDerivative · entry 1 Corcoran Andrea · CIK 0001296996 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.